Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
RHHBY's Cash-to-Debt is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. RHHBY: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
RHHBY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.18 Max: N/A
Current: 0.41
Equity-to-Asset 0.31
RHHBY's Equity-to-Asset is ranked lower than
87% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RHHBY: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
RHHBY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.38 Max: 0.59
Current: 0.31
0.1
0.59
Interest Coverage 20.45
RHHBY's Interest Coverage is ranked lower than
66% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. RHHBY: 20.45 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: N/A
Current: 20.45
Piotroski F-Score: 9
Altman Z-Score: 3.77
Beneish M-Score: -2.75
WACC vs ROIC
4.95%
27.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.82
RHHBY's Operating Margin % is ranked higher than
90% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. RHHBY: 27.82 )
Ranked among companies with meaningful Operating Margin % only.
RHHBY' s Operating Margin % Range Over the Past 10 Years
Min: 25.03  Med: 28.89 Max: 33.69
Current: 27.82
25.03
33.69
Net Margin % 18.93
RHHBY's Net Margin % is ranked higher than
85% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. RHHBY: 18.93 )
Ranked among companies with meaningful Net Margin % only.
RHHBY' s Net Margin % Range Over the Past 10 Years
Min: 15.87  Med: 18.83 Max: 22.97
Current: 18.93
15.87
22.97
ROE % 45.35
RHHBY's ROE % is ranked higher than
96% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. RHHBY: 45.35 )
Ranked among companies with meaningful ROE % only.
RHHBY' s ROE % Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 45.35
19.94
102.95
ROA % 12.65
RHHBY's ROA % is ranked higher than
85% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. RHHBY: 12.65 )
Ranked among companies with meaningful ROA % only.
RHHBY' s ROA % Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.65
10.33
17.58
ROC (Joel Greenblatt) % 62.96
RHHBY's ROC (Joel Greenblatt) % is ranked higher than
88% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. RHHBY: 62.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RHHBY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.39  Med: 64.84 Max: 84.52
Current: 62.96
52.39
84.52
3-Year Revenue Growth Rate 1.40
RHHBY's 3-Year Revenue Growth Rate is ranked lower than
66% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. RHHBY: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RHHBY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78  Med: 1.5 Max: 390.8
Current: 1.4
-78
390.8
3-Year EBITDA Growth Rate -2.20
RHHBY's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. RHHBY: -2.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RHHBY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -88.5  Med: 2.7 Max: 268.9
Current: -2.2
-88.5
268.9
3-Year EPS without NRI Growth Rate -4.90
RHHBY's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. RHHBY: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RHHBY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.9  Med: 5.8 Max: 340.9
Current: -4.9
-4.9
340.9
GuruFocus has detected 6 Warning Signs with Roche Holding AG $RHHBY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RHHBY's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RHHBY Guru Trades in Q2 2016

Mairs and Power 4,005,602 sh (+47.07%)
Ken Fisher 15,142,209 sh (+1.58%)
» More
Q3 2016

RHHBY Guru Trades in Q3 2016

Mairs and Power 4,644,431 sh (+15.95%)
Ken Fisher 15,126,928 sh (-0.10%)
» More
Q4 2016

RHHBY Guru Trades in Q4 2016

Mairs and Power 4,982,597 sh (+7.28%)
Ken Fisher 14,946,458 sh (-1.19%)
» More
Q1 2017

RHHBY Guru Trades in Q1 2017

Ken Fisher 15,104,940 sh (+1.06%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, OTCPK:NVSEF, NYSE:MRK, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:LLY, NYSE:JNJ, NYSE:BMY, NYSE:AZN, OTCPK:SZUKF, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHF » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Headquarter Location:Switzerland
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group has been bolstered by the acquisition of Ventana in 2008. Oncology products account for more than 60% of pharmaceutical sales, and professional diagnostics for more than half of diagnostic-related sales.

Top Ranked Articles about Roche Holding AG

Roche's Leukemia Drug Approved for Next Step in Europe Venclyxto drug gets 'conditional marketing' approval from European Commission
Roche (RHHBY) announced on Dec. 8 that Venclyxto (venetoclax), a drug that is used as therapy in patients chronically affected with lymphocytic leukemia, has been authorized by the European Commission, achieving the “conditional marketing.” Read more...
Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Therapy is used to treat chronic lymphocytic leukaemia
Today Roche (RHHBY) reported a positive opinion concerning Venclyxt (venetoclax) from the European Union Committee for Medicinal Products for Human Use (CHMP). Read more...
Innovative Diagnostic and Therapeutic Products Seen at Roche Roche is arguably the strongest company in the biotech field​
In the world of biotechnology and pharmaceuticals, arguably the largest in the field is the company known as Roche (RHHBY). Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver great benefits to patients and healthcare professionals, from early detection and prevention of disease to treatment and treatment monitoring. Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.23
RHHBY's PE Ratio is ranked higher than
62% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. RHHBY: 23.23 )
Ranked among companies with meaningful PE Ratio only.
RHHBY' s PE Ratio Range Over the Past 10 Years
Min: 0.13  Med: 15.17 Max: 26.92
Current: 23.23
0.13
26.92
Forward PE Ratio 16.26
RHHBY's Forward PE Ratio is ranked lower than
51% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. RHHBY: 16.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.23
RHHBY's PE Ratio without NRI is ranked higher than
62% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. RHHBY: 23.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
RHHBY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.13  Med: 15.17 Max: 26.92
Current: 23.23
0.13
26.92
Price-to-Owner-Earnings 17.08
RHHBY's Price-to-Owner-Earnings is ranked higher than
76% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. RHHBY: 17.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RHHBY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.09  Med: 13.92 Max: 19.34
Current: 17.08
0.09
19.34
PB Ratio 9.30
RHHBY's PB Ratio is ranked lower than
87% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. RHHBY: 9.30 )
Ranked among companies with meaningful PB Ratio only.
RHHBY' s PB Ratio Range Over the Past 10 Years
Min: 0.03  Med: 10.04 Max: 14.96
Current: 9.3
0.03
14.96
PS Ratio 4.40
RHHBY's PS Ratio is ranked lower than
62% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. RHHBY: 4.40 )
Ranked among companies with meaningful PS Ratio only.
RHHBY' s PS Ratio Range Over the Past 10 Years
Min: 0.02  Med: 3.3 Max: 5.04
Current: 4.4
0.02
5.04
Price-to-Free-Cash-Flow 22.22
RHHBY's Price-to-Free-Cash-Flow is ranked higher than
55% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. RHHBY: 22.22 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RHHBY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.09  Med: 12.92 Max: 22.37
Current: 22.22
0.09
22.37
Price-to-Operating-Cash-Flow 14.82
RHHBY's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. RHHBY: 14.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RHHBY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.07  Med: 10.77 Max: 15.66
Current: 14.82
0.07
15.66
EV-to-EBIT 17.05
RHHBY's EV-to-EBIT is ranked higher than
62% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. RHHBY: 17.05 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.6  Med: 11.8 Max: 19.8
Current: 17.05
-0.6
19.8
EV-to-EBITDA 13.17
RHHBY's EV-to-EBITDA is ranked higher than
65% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. RHHBY: 13.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.5  Med: 10 Max: 15.7
Current: 13.17
-0.5
15.7
PEG Ratio 21.09
RHHBY's PEG Ratio is ranked lower than
95% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.90 vs. RHHBY: 21.09 )
Ranked among companies with meaningful PEG Ratio only.
RHHBY' s PEG Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.34 Max: 23.21
Current: 21.09
0.01
23.21
Shiller PE Ratio 22.22
RHHBY's Shiller PE Ratio is ranked higher than
80% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. RHHBY: 22.22 )
Ranked among companies with meaningful Shiller PE Ratio only.
RHHBY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.18  Med: 21.61 Max: 26.44
Current: 22.22
0.18
26.44
Current Ratio 1.27
RHHBY's Current Ratio is ranked lower than
81% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. RHHBY: 1.27 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.33 Max: 3.75
Current: 1.27
1.19
3.75
Quick Ratio 0.92
RHHBY's Quick Ratio is ranked lower than
81% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. RHHBY: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.93 Max: 3.22
Current: 0.92
0.86
3.22
Days Inventory 178.94
RHHBY's Days Inventory is ranked lower than
76% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. RHHBY: 178.94 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 178.94
143.33
186.16
Days Sales Outstanding 63.22
RHHBY's Days Sales Outstanding is ranked higher than
60% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. RHHBY: 63.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.14  Med: 73.14 Max: 84.09
Current: 63.22
63.14
84.09
Days Payable 76.14
RHHBY's Days Payable is ranked higher than
55% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. RHHBY: 76.14 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 76.14
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.16
RHHBY's Dividend Yield % is ranked higher than
81% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. RHHBY: 3.16 )
Ranked among companies with meaningful Dividend Yield % only.
RHHBY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.03  Med: 2.81 Max: 4.55
Current: 3.16
0.03
4.55
Dividend Payout Ratio 0.73
RHHBY's Dividend Payout Ratio is ranked lower than
81% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. RHHBY: 0.73 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RHHBY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0.29 Max: 0.78
Current: 0.73
0
0.78
3-Year Dividend Growth Rate 3.30
RHHBY's 3-Year Dividend Growth Rate is ranked lower than
62% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. RHHBY: 3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RHHBY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -75.5  Med: 21.05 Max: 414.3
Current: 3.3
-75.5
414.3
Forward Dividend Yield % 3.14
RHHBY's Forward Dividend Yield % is ranked higher than
79% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. RHHBY: 3.14 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.96
RHHBY's 5-Year Yield-on-Cost % is ranked higher than
78% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. RHHBY: 3.96 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RHHBY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.33  Med: 3.69 Max: 5.7
Current: 3.96
1.33
5.7
3-Year Average Share Buyback Ratio 0.10
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. RHHBY: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -364.2  Med: 0.1 Max: 62.8
Current: 0.1
-364.2
62.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 381.27
RHHBY's Price-to-Tangible-Book is ranked lower than
100% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. RHHBY: 381.27 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RHHBY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22  Med: 41.35 Max: 1920.4
Current: 381.27
1.22
1920.4
Price-to-Intrinsic-Value-Projected-FCF 1.71
RHHBY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. RHHBY: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RHHBY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.12  Med: 1.72 Max: 3.89
Current: 1.71
1.12
3.89
Price-to-Median-PS-Value 1.11
RHHBY's Price-to-Median-PS-Value is ranked higher than
54% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. RHHBY: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RHHBY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.02 Max: 212.25
Current: 1.11
0.02
212.25
Price-to-Graham-Number 19.84
RHHBY's Price-to-Graham-Number is ranked lower than
99% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. RHHBY: 19.84 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RHHBY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.91  Med: 6.53 Max: 636.76
Current: 19.84
1.91
636.76
Earnings Yield (Greenblatt) % 5.87
RHHBY's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. RHHBY: 5.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RHHBY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5  Med: 7.1 Max: 60
Current: 5.87
5
60
Forward Rate of Return (Yacktman) % 6.31
RHHBY's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. RHHBY: 6.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RHHBY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.5  Med: 8.85 Max: 789
Current: 6.31
4.5
789

More Statistics

Revenue (TTM) (Mil) $50,877
EPS (TTM) $ 1.40
Beta0.64
Short Percentage of Float0.00%
52-Week Range $25.25 - 33.77
Shares Outstanding (Mil)6,815.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 55,001 59,514 67,013
EPS ($) 1.95 2.13 2.50
EPS without NRI ($) 1.95 2.13 2.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.40%
Dividends per Share ($) 1.05 1.13 1.18
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Roche Diagnostics recognizes Sentara Consolidated Laboratories as Roche Molecular Center of Excellen Apr 19 2017 
Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases Apr 12 2017 
Roche launches new global Certified Provider Program for Target Enrichment in Genomic Sequencing Apr 11 2017 
A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 
Blake Insomnia CEO Dreams of Improving Sleep Jan 04 2017 
Roche's Leukemia Drug Approved for Next Step in Europe Dec 11 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 

More From Other Websites
India's antitrust watchdog orders probe into Roche cancer drug Apr 26 2017
New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and... Apr 26 2017
ETFs with exposure to Roche Holding AG : April 21, 2017 Apr 21 2017
Roche Holding AG : RHHBY-US: Dividend Analysis : March 17th, 2017 (record date) : By the numbers :... Apr 21 2017
Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS... Apr 19 2017
After Johnson & Johnson Earnings, Buy These Pharma Stocks Apr 18 2017
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion Apr 18 2017
Roche's Tecentriq wins FDA approval for treating advanced bladder cancer Apr 17 2017
Roche's Hemophilia A Drug Positive in Second Phase III Study Apr 17 2017
FDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approval as Initial Treatment for... Apr 17 2017
Roche's Genentech says its drug for diabetes complication has been approved by FDA Apr 17 2017
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading... Apr 17 2017
Roche's emicizumab haemophilia drug shows positive results with children Apr 17 2017
Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with... Apr 17 2017
Could Bristol's Drug Help Biogen Take AbbVie In Alzheimer's? Apr 13 2017
Roche Launches Antibody Test to Diagnose Prostate Cancer Apr 13 2017
Bristol-Myers to license two drugs to Biogen, Roche Apr 13 2017
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops Apr 13 2017
Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases Apr 12 2017
Protalix Cystic Fibrosis Drug Study Results Worsen Over Time Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)